Abstract: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically.

Abstract: A method for providing push-to-talk (PTT) so as to conference between a plurality of user equipments (UEs) serving as clients in a mobile communication network including a PTT over cellular (PoC) server, a conference server, and a mixer for mixing for the conference. The method comprises performing a request procedure for switching over to the conference during a PoC session between the UEs; performing a conference client invitation or participation procedure for opening a conference session through the conference server; and performing a procedure for releasing the conference session between the PoC server and the UEs. The method can switch over to a conference service during a PTT service without newly initializing the conference service after completing an old PoC session, and can also switch over to bidirectional communication between all or some of the participants during a PoC session which is using unidirectional communications.

Abstract: The present invention relates to a variant of Lkn-1(shLkn-1) with enhanced biological activity, which is a truncated form of Lkn-1, a process for preparing a recombinant shLkn-1 by employing expression vector therefor and pharmaceutical application of the said protein. shLkn-1 is generated by missing 26 amino acid residues from the amino terminus of Lkn-1 to contain 66 amino acids. Recombinant shLkn-1 inhibits colony formation and cell proliferation in vivo, which suggests that it can be used as a potential drug for the antibody production, the treatment during HIV-1 infection, the protection of bone marrow stem cells during chemotherapy or radiotherapy, and the inhibition of leukemia.